[1] |
DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15( 2): 258- 282. DOI: 10.1007/s12072-021-10144-3.
|
[2] |
Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
|
[3] |
MAO Y, MA S, LIU C, et al. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update[J]. Hepatol Int, 2024, 18( 2): 384- 419. DOI: 10.1007/s12072-023-10633-7.
|
[4] |
Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J].[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
|
[5] |
NUNES DRDCMA, MONTEIRO CSJ, DOS SANTOS JL. Herb-induced liver injury-a challenging diagnosis[J]. Healthcare(Basel), 2022, 10( 2): 278. DOI: 10.3390/healthcare10020278.
|
[6] |
LARREY D, VIAL T, PAUWELS A, et al. Hepatitis after germander(Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity[J]. Ann Intern Med, 1992, 117( 2): 129- 132. DOI: 10.7326/0003-4819-117-2-129.
|
[7] |
LIN G, WANG JY, LI N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol, 2011, 54( 4): 666- 673. DOI: 10.1016/j.jhep.2010.07.031.
|
[8] |
GARCÍA-CORTÉS M, STEPHENS C, LUCENA MI, et al. Causality assessment methods in drug induced liver injury: Strengths and weaknesses[J]. J Hepatol, 2011, 55( 3): 683- 691. DOI: 10.1016/j.jhep.2011.02.007.
|
[9] |
TESCHKE R, DANAN G. Worldwide use of RUCAM for causality assessment in 81, 856 idiosyncratic DILI and 14, 029 HILI cases published 1993-mid 2020: A comprehensive analysis[J]. Medicines(Basel), 2020, 7( 10): 62. DOI: 10.3390/medicines7100062.
|
[10] |
TESCHKE R, ZHU Y, JING J. Herb-induced liver injury in Asia and current role of RUCAM for causality assessment in 11, 160 published cases[J]. J Clin Transl Hepatol, 2020, 8( 2): 200- 214. DOI: 10.14218/jcth.2020.00009.
|
[11] |
KOTHADIA JP, KAMINSKI M, SAMANT H, et al. Hepatotoxicity associated with use of the weight loss supplement Garcinia cambogia: A case report and review of the literature[J]. Case Reports Hepatol, 2018, 2018: 6483605. DOI: 10.1155/2018/6483605.
|
[12] |
SMITH RJ, BERTILONE C, ROBERTSON AG. Fulminant liver failure and transplantation after use of dietary supplements[J]. Med J Aust, 2016, 204( 1): 30- 32. DOI: 10.5694/mja15.00816.
|
[13] |
LAUBE R, LIU K. An unwanted complement: Rare case of potential liver injury induced by an interaction between ginseng and atorvastatin[J]. Br J Clin Pharmacol, 2019, 85( 7): 1612- 1613. DOI: 10.1111/bcp.13927.
|
[14] |
HAYASHI PH, LUCENA MI, FONTANA RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI[J]. Hepatology, 2022, 76( 1): 18- 31. DOI: 10.1002/hep.32327.
|
[15] |
ZHAO XY, WANG Y, LAI RT, et al. Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients[J]. Hepatol Commun, 2024, 8( 4): e0235. DOI: 10.1097/HC9.0000000000000235.
|
[16] |
ROCKEY DC, SEEFF LB, ROCHON J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method[J]. Hepatology, 2010, 51( 6): 2117- 2126. DOI: 10.1002/hep.23577.
|
[17] |
State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine[J]. J Clin Hepatol, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.
国家药品监督管理局. 中药药源性肝损伤临床评价技术指导原则[J]. 临床肝胆病杂志, 2018, 34( 7): 1403- 1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.
|
[18] |
HE TT, LIANG QS, WANG LP, et al. Diagnostic values of integrated evidence chain, Roussel Uclaf Causality Assessment Method, and Structured Expert Opinion Process method for drug-induced liver injury[J]. J Clin Hepatol, 2022, 38( 1): 141- 147. DOI: 10.3969/j.issn.1001-5256.2022.01.022.
何婷婷, 梁庆升, 王丽苹, 等. 整合证据链、Roussel Uclaf因果关系评价法、结构化专家观点程序对药物性肝损伤的诊断效用分析[J]. 临床肝胆病杂志, 2022, 38( 1): 141- 147. DOI: 10.3969/j.issn.1001-5256.2022.01.022.
|
[19] |
CHAU TN, CHEUNG WI, NGAN T, et al. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method(RUCAM)[J]. Clin Toxicol(Phila), 2011, 49( 1): 34- 39. DOI: 10.3109/15563650.2010.537662.
|
[20] |
HOOFNAGLE JH, BONKOVSKY HL, PHILLIPS EJ, et al. HLA-B*35:01 and green tea-induced liver injury[J]. Hepatology, 2021, 73( 6): 2484- 2493. DOI: 10.1002/hep.31538.
|
[21] |
LI CP, RAO T, CHEN XP, et al. HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70( 1): 346- 357. DOI: 10.1002/hep.30660.
|
[22] |
SARGES P, STEINBERG JM, LEWIS JH. Drug-induced liver injury: Highlights from a review of the 2015 literature[J]. Drug Saf, 2016, 39( 9): 801- 821.
|
[23] |
LEWIS PJ, DEAR J, PLATT V, SIMPSON KJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury[J]. Hepatology, 2011, 54( 5): 1767- 1776.
|
[24] |
JIE Z, et al. Integrated expression profiles of mRNA and microRNA in the liver of Fructus Meliae Toosendan water extract injured mice[J]. Frontiers in Pharmacology, 2015, 6: 236. DOI: 10.3389/fphar.2015.00236.
|
[1] | Jiaxi MA, Tiantian YAO, Hao CHENG, Dan LIU, Yuhan ZHANG, Siyuan DU, Linfei DONG, Linhui HU, Yan WANG, Guiqiang WANG. Value of different assessment scales in the diagnosis of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(6): 1203-1208. doi: 10.12449/JCH240621 |
[2] | Xueying LIU, Huihui SHI, Haowen WANG, Tao YANG. The material basis and toxic mechanism of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1512-1518. doi: 10.12449/JCH240802 |
[3] | Tingting HE, Zhaofang BAI, Jiabo WANG, Xiaohe XIAO. Phenotypic characteristics and toxicological mechanisms of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1525-1532. doi: 10.12449/JCH240804 |
[4] | Xin SUN, Qiong LUO, Tao YANG, Chenghai. LIU. Management and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1538-1542. doi: 10.12449/JCH240806 |
[5] | Hui ZHENG, Rong SUN. Influence of combined drug administration on herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1519-1524. doi: 10.12449/JCH240803 |
[6] | Chenghai LIU. Research advances and challenges in herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1505-1511. doi: 10.12449/JCH240801 |
[7] | Yu WANG, Qiong LUO, Shu LI, Xiaoping SHEN, Shuang LI, Yanyan TAO, Chenghai LIU. A preliminary study on the peripheral seroimmunological characteristics of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(5): 1097-1100. doi: 10.3969/j.issn.1001-5256.2022.05.023 |
[8] | Tingting HE, Qingsheng LIANG, Liping WANG, Longxin LIANG, Xiaohan LI, Yanfei CUI, Jing JING, Zhaofang BAI, Man GONG, Ruilin WANG. Diagnostic values of integrated evidence chain, Roussel Uclaf Causality Assessment Method, and Structured Expert Opinion Process method for drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(1): 141-147. doi: 10.3969/j.issn.1001-5256.2022.01.022 |
[9] | Rongtao LAI, Qing XIE. Clinical features of drug-induced liver failure and related diagnosis and treatment strategies[J]. Journal of Clinical Hepatology, 2021, 37(11): 2534-2538. doi: 10.3969/j.issn.1001-5256.2021.11.006 |
[10] | Luyuan WANG, Minjie JIANG, Pujun GAO. Association between human leukocyte antigen gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(2): 475-479. doi: 10.3969/j.issn.1001-5256.2021.02.048 |
[11] | Yongfeng YANG. Pathological features and pathological diagnosis of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2530-2533. doi: 10.3969/j.issn.1001-5256.2021.11.005 |
[12] | Liang XiaoNan, Song YiRan, Li Zhou, Wang Yang, Luo YuXin, Huo XiaoXia, Yin FengRong, Zhang XiaoLan. Hepatitis-associated aplastic anemia following drug-induced liver injury:A case report[J]. Journal of Clinical Hepatology, 2020, 36(8): 1824-1826. doi: 10.3969/j.issn.1001-5256.2020.08.030 |
[13] | Wang QiaoLing, Zou ZhengSheng. Association between cytochrome P450 gene polymorphism and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(5): 1150-1153. doi: 10.3969/j.issn.1001-5256.2020.05.045 |
[14] | Luo Qiong, Zhu GeRui, Gu HongTu, Liu Kun, Chen GaoFeng, Xing Feng, Tao YanYan, Liu ChengHai. Liver histopathological features of patients with drug-induced liver injury due to Chinese herbal medicine or Western medicine: A comparative analysis of 50 cases[J]. Journal of Clinical Hepatology, 2020, 36(3): 596-601. doi: 10.3969/j.issn.1001-5256.2020.03.025 |
[15] | Xing Lu, Wang Yu, Tao YanYan, Liu ChengHai. Clinical evaluation and prognosis prediction of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(12): 2820-2823. doi: 10.3969/j.issn.1001-5256.2019.12.039 |
[16] | Chen Jun. Drug-induced liver injury caused by Chinese herbal medicine cannot be neglected[J]. Journal of Clinical Hepatology, 2018, 34(6): 1169-1171. doi: 10.3969/j.issn.1001-5256.2018.06.006 |
[17] | Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007 |
[18] | Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 835-843. doi: 10.3969/j.issn.1001-5256.2016.05.003 |
[19] | Zhu Yun, Wang RuiLin, Sun XueYing, Yu SiMiao, Jing Jing, Wang JiaBo, He TingTing, Huang YiXue, Wang LiPing, Sun YongQiang. Guiding significance of Guideline for diagnosis and treatment of herb-induced liver injury in clinical diagnosis: a retrospective analysis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2159-2162. doi: 10.3969/j.issn.1001-5256.2016.11.032 |
[20] | Li Yang, Xu JianMing. Clinical analysis of 11 cases of hepatic veno-occlusive disease caused by Chinese herbal medicine[J]. Journal of Clinical Hepatology, 2011, 27(2): 140-142. |